YYSW001
YYSW001 is a selective and orally acrive JAK1 inhibitor with an IC50 of 6 nM and a Kd of 32.32 μM. YYSW001 blocks JAK1-dependent phosphorylation of STAT6, as well as IL-6-induced phosphorylation of STAT3. YYSW001 suppresses pro-inflammatory cytokine levels, reduces paw swelling, lowers clinical arthritis scores, alleviates joint damage and decreases bone loss. YYSW001 is applicable for the research of rheumatoid arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2763672-36-0
- Formule: C18H20F5N5O
- Masse moléculaire:417.38
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
JAK1 |
STAT3 |
STAT6 |
In Vitro
YYSW001 (2 h) potently inhibits the JAK1-dependent STAT6 pathway in THP-1 cells (IC50 = 0.041 μM), while only exerting weak inhibitory activity against the JAK2-dependent STAT5 pathway in TF-1 cells (IC50 = 5.530 μM)[1].
YYSW001 (72 h) potently inhibits the proliferation of Ba/F3-TEL-JAK1 cells (IC50 = 290.2 nM), while exhibits extremely low activity against Ba/F3-TEL-JAK2, Ba/F3-TEL-JAK3 and Ba/F3-TEL-TYK2 cells[1].
YYSW001 (15 min) inhibits IL-6-induced JAK1-dependent STAT3 phosphorylation in human whole blood cells (IC50 = 7065.0 nM in CD3+ T cells, 3001.0 nM in CD14+ monocytes), and shows extremely weak inhibitory activity against GM-CSF-induced JAK2-dependent STAT5 phosphorylation[1].
YYSW001 exhibits favorable in vitro ADME properties, including excellent liver microsomal stability and plasma stability, extremely low inhibitory activity against CYP3A4 and hERG, moderate permeability, and moderate plasma protein binding rate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ba/F3-engineered cell lines (Ba/F3-TEL-JAK1, Ba/F3-TEL-JAK2, Ba/F3-TEL-JAK3, Ba/F3-TEL-TYK2)
-
Concentration:serial 2- or 3-fold dilutions (nine gradients)
-
Incubation Time:72 h
-
Result:Exhibited potent inhibitory activity against Ba/F3-TEL-JAK1 cells with an IC50 of 290.2 nM.
Showed negligible inhibition against Ba/F3-TEL-JAK2, Ba/F3-TEL-JAK3, and Ba/F3-TEL-TYK2 cells (IC50 > 10000.0 nM for all three cell lines).
Achieved a cellular JAK1/JAK2 selectivity ratio of 38.6.
Parmacokinetics
| Species | Dose | Route | AUC0-t | AUC0-∞ | Cmax | Tmax | T1/2 | MRT0-∞ | V | CL | F | Vd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 3 mg/kg | i.v. | 3831.25 h·μg/L | 4051.12 h·μg/L | / | / | 2.8 h | 3.7 h | / | 0.7 L/h/kg | / | 3.1 L/kg |
| Rat[1] | 3 mg/kg | p.o. | 2277.65 h·μg/L | 2503.58 h·μg/L | 328.61 μg/L | 3.0 h | 2.8 h | 5..8 h | 5.0 L/kg | 1.2 L/h/kg | 61.8 % | / |
| Rat[1] | 10 mg/kg | p.o. | 8543.24 h·μg/L | 8861.88 h·μg/L | 1323.53 μg/L | 3.2 h | 2.2 h | 5.0 h | 3.6 L/kg | 1.1 L/h/kg | 65.6 % | / |
| Rat[1] | 30 mg/kg | p.o. | 25905.37 h·μg/L | 26291.77 h·μg/L | 3300.77 μg/L | 2.9 h | 2.5 h | 6.6 h | 3.3 L/kg | 0.9 L/h/kg | 64.9 % | / |
In Vivo
YYSW001 (1-30 mg/kg; p.o.; twice daily; 14 days) exhibits a clear dose-dependent anti-arthritic effect in a rat adjuvant-induced arthritis model[1].
YYSW001 (100-200 mg/kg; p.o.; once daily; 7 days) shows no significant safety concerns in rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) rats (collagen-induced arthritis model)[1]
-
Dosage:3 mg/kg; 10 mg/kg
-
Administration:i.g.; twice daily; 14 days
-
Result:Reversed disease-induced body weight loss.
Significantly reduced hind paw swelling
Decreased clinical arthritis scores.
Suppressed serum levels of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α to near-normal levels.
Substantially preserved joint architecture and reduced bone loss compared to the vehicle group.
Chemical Information
-
CAS No. 2763672-36-0
-
Masse moléculaire 417.38
-
Formule C18H20F5N5O
-
SMILES
O[C@@H](C1=NC2=CN=C3NC=CC3=C2N1[C@@H]4CN(CC4)CCC(C(F)(F)F)(F)F)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)